Fintel reports that on May 31, 2024, Piper Sandler initiated coverage of Immunome (NasdaqCM:IMNM) with a Overweight recommendation.
Analyst Price Forecast Suggests 141.23% Upside
As of May 22, 2024, the average one-year price target for Immunome is 36.04. The forecasts range from a low of 33.33 to a high of $39.90. The average price target represents an increase of 141.23% from its latest reported closing price of 14.94.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Immunome is 291MM, an increase of 2,192.04%. The projected annual non-GAAP EPS is 4.30.
What is the Fund Sentiment?
There are 163 funds or institutions reporting positions in Immunome. This is an increase of 79 owner(s) or 94.05% in the last quarter. Average portfolio weight of all funds dedicated to IMNM is 0.15%, an increase of 15.54%. Total shares owned by institutions increased in the last three months by 77.22% to 38,208K shares. 
The put/call ratio of IMNM is 0.16, indicating a bullish outlook.
What are Other Shareholders Doing?
Redmile Group holds 4,890K shares representing 8.15% ownership of the company. In its prior filing, the firm reported owning 3,879K shares , representing an increase of 20.66%. The firm increased its portfolio allocation in IMNM by 198.33% over the last quarter.
EcoR1 Capital holds 3,879K shares representing 6.47% ownership of the company. No change in the last quarter.
Price T Rowe Associates holds 2,246K shares representing 3.74% ownership of the company. In its prior filing, the firm reported owning 1,051K shares , representing an increase of 53.19%. The firm increased its portfolio allocation in IMNM by 123.41% over the last quarter.
Point72 Asset Management holds 1,642K shares representing 2.74% ownership of the company. In its prior filing, the firm reported owning 683K shares , representing an increase of 58.43%. The firm increased its portfolio allocation in IMNM by 456.07% over the last quarter.
Janus Henderson Group holds 1,538K shares representing 2.57% ownership of the company. In its prior filing, the firm reported owning 1,391K shares , representing an increase of 9.55%. The firm increased its portfolio allocation in IMNM by 133.15% over the last quarter.
Immunome Background Information
(This description is provided by the company.)
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initial focus is on developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
